石藥集團(01093)藥物SYH2061注射液獲美國批准開展臨床試驗

　　石藥集團(01093)公布，雙鏈小干擾RNA藥物SYH2061注射液已獲美國食品藥品監督管理局批准，可在美國開展臨床試驗。

　　該集團指，該產品已在10月獲國家藥品監督管理局批准在內地開展臨床試驗。產品適用於治療IgA腎病等。
《經濟通通訊社25日專訊》

樂本健【年度感謝祭】維柏健及natural Factors全線2件7折► 了解詳情

備註：	即時報價更新時間為18/12/2025 17:59
	港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。